GUD — Knight Therapeutics Share Price
0.000.00%
Last trade - 00:00- CA$565.86m
- CA$452.20m
- CA$371.30m
- 96
- 42
- 47
- 66
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 88.82 | ||
| PEG Ratio (f) | 3.48 | ||
| EPS Growth (f) | 34.32% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.71 | ||
| Price to Tang. Book | 1.33 | ||
| Price to Free Cashflow | 117.69 | ||
| Price to Sales | 1.52 | ||
| EV to EBITDA | 7.47 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 0.87% | ||
| Return on Equity | 0.56% | ||
| Operating Margin | 1.99% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 199.52 | 243.48 | 293.56 | 328.2 | 371.3 | 397.74 | 438.5 | 50.9% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +104.05 | -66.5 | n/a | n/a | n/a | +26.81 | +48.21 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.
Directors
- James Gale CHM (71)
- Samira Sakhia PRE (52)
- Jonathan Goodman CEO (53)
- Arvind Utchanah CFO
- Amal Khouri OTH
- Robert Lande IND (58)
- Janice Murray IND (55)
- Nicolas Sujoy IND (45)
- Michael Tremblay IND (68)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 1st, 2015
- Public Since
- February 28th, 2014
- No. of Employees
- 745
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Toronto Stock Exchange
- Shares in Issue
- 99,448,484
- Address
- 3400 De Maisonneuve Blvd W, MONTREAL, H3Z 3B8
- Web
- https://knighttx.com/CA/fr/about-us/
- Phone
- +1 null5144844483
- Contact
- Samira Sakhia
- Auditors
- Ernst & Young LLP
Upcoming Events for GUD
Knight Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Knight Therapeutics Inc Earnings Release
Similar to GUD
Aptose Biosciences
Toronto Stock Exchange
Aurora Cannabis
Toronto Stock Exchange
Auxly Cannabis
Toronto Stock Exchange
Bausch Health Companies
Toronto Stock Exchange
Canopy Growth
Toronto Stock Exchange
FAQ
What is the Knight Therapeutics share price?
As of Today at 21:36 UTC, shares in Knight Therapeutics are trading at CA$5.69. This share price information is delayed by 15 minutes.
How has the Knight Therapeutics share price performed this year?
Shares in Knight Therapeutics last closed at CA$5.69 and the price had moved by -2.9% over the past 365 days. In terms of relative price strength the Knight Therapeutics share price has underperformed the Toronto Stock Exchange 300 Composite Index by -12.48% over the past year.
What are the analyst and broker recommendations for Knight Therapeutics?
The overall consensus recommendation for Knight Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Knight Therapeutics dividend yield?
Knight Therapeutics does not currently pay a dividend.
Does Knight Therapeutics pay a dividend?
Knight Therapeutics does not currently pay a dividend.
When does Knight Therapeutics next pay dividends?
Knight Therapeutics does not currently pay a dividend.
How do I buy Knight Therapeutics shares?
To buy shares in Knight Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Knight Therapeutics?
As of the previous close price of CA$5.69, shares in Knight Therapeutics had a market capitalisation of CA$565.86m.
Where are Knight Therapeutics shares listed?
Here are the trading details for Knight Therapeutics:
- Country of listing: Canada
- Exchange: TOR
- Ticker Symbol: GUD
What kind of share is Knight Therapeutics?
Based on an overall assessment of its quality, value and momentum Knight Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Knight Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Knight Therapeutics is CA$7.56. That is 32.86% above the last closing price of CA$5.69.
Analysts covering Knight Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of CA$0.06 for the next financial year.
Find out moreWhat is the trend in the Knight Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Knight Therapeutics. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +2.01%.
As of the last closing price of CA$5.69, shares in Knight Therapeutics were trading +1% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Knight Therapeutics PE Ratio?
The Knight Therapeutics PE ratio based on its reported earnings over the past 12 months is 88.82. The shares last closed at CA$5.69.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Knight Therapeutics?
Knight Therapeutics' management team is headed by:
- James Gale - CHM
- Samira Sakhia - PRE
- Jonathan Goodman - CEO
- Arvind Utchanah - CFO
- Amal Khouri - OTH
- Robert Lande - IND
- Janice Murray - IND
- Nicolas Sujoy - IND
- Michael Tremblay - IND